GlassScriptPhysician profile
Sohail A Minhas
NPI 1053303750
$19,431.05
in general payments reported to CMS, 2019-2025
68 companies · $5,857 in 2025
The $5,857 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,245 · 2020: $491 · 2021: $675 · 2022: $2,709 · 2023: $3,575 · 2024: $3,880 · 2025: $5,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,947 · Consulting Fee: $2,680 · Education: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,946.63 |
| Consulting Fee | $2,680.00 |
| Education | $684.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,252.81 | 2019-2025 | Imfinzi, Enhertu |
| Janssen Biotech, INC. | $1,531.89 | 2019-2025 | Darzalex, Tecvayli, Carvykti |
| Novartis Pharmaceuticals Corporation | $1,364.30 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,047.68 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $1,043.27 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $1,030.18 | 2019-2025 | |
| Lilly USA, LLC | $725.35 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $710.49 | 2020-2025 | Xtandi, Padcev, Xospata |
| Gilead Sciences, INC. | $601.39 | 2021-2025 | Trodelvy |
| Exelixis INC. | $560.68 | 2019-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $530.41 | 2019-2025 | Ninlaro, Gattex |
| Amgen INC. | $512.55 | 2019-2023 | Lumakras, Nplate, Xgeva |
| Seagen INC. | $485.77 | 2019-2023 | Padcev, Tukysa |
| Abbvie INC. | $465.16 | 2019-2025 | |
| Glaxosmithkline, LLC. | $427.66 | 2021-2025 | Ojjaara, Jemperli, Zejula |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $410.67 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Celgene Corporation | $380.63 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Eisai INC. | $374.76 | 2019-2025 | |
| Genzyme Corporation | $334.29 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $254.42 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $222.82 | 2022-2025 | Libtayo |
| Tempus Ai, INC | $210.98 | 2024-2025 | Xt Cdx |
| Emd Serono, INC. | $202.26 | 2023-2025 | Bavencio, Tepmetko |
| Incyte Corporation | $199.69 | 2019-2025 | Monjuvi, Pemazyre, Zynyz |
| Alexion Pharmaceuticals, INC. | $194.34 | 2021-2025 | Ultomiris |
| Puma Biotechnology, INC. | $162.69 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $156.86 | 2019-2023 | Imbruvica |
| Genentech USA, INC. | $154.33 | 2019-2024 | Tecentriq, Phesgo, Polivy |
| Recordati_rare_diseases_inc. | $152.41 | 2024 | Sylvant |
| Stemline Therapeutics INC. | $149.80 | 2022-2025 | Orserdu |
| Rigel Pharmaceuticals, INC. | $141.09 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Beone Medicines USA, INC. | $114.10 | 2025 | Tevimbra, Brukinsa |
| Taiho Oncology, INC. | $103.65 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.41 | 2020-2025 | |
| Beigene USA, INC. | $73.19 | 2024-2025 | Brukinsa, Tevimbra |
| Genmab U.S., INC. | $69.20 | 2024-2025 | Epkinly |
| Mirati Therapeutics, INC. | $69.15 | 2023-2024 | Krazati |
| Servier Pharmaceuticals LLC | $68.65 | 2020-2024 | |
| Array Biopharma INC | $61.42 | 2025 | Mektovi, Tukysa, Braftovi |
| Coherus Oncology, INC. | $60.79 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $57.63 | 2023 | Orgovyx |
| Janssen Pharmaceuticals, INC | $54.32 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $53.91 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $46.81 | 2024-2025 | Xpovio |
| Secura Bio, INC. | $44.10 | 2019 | |
| Biocompatibles, INC. | $41.03 | 2019 | |
| Sobi, INC | $36.60 | 2022 | |
| Springworks Therapeutics, INC. | $33.88 | 2024 | Ogsiveo |
| Tolmar Pharmaceuticals, INC. | $32.02 | 2021 | |
| Azurity Pharmaceuticals, INC. | $30.00 | 2025 | Danziten |
| Sanofi US Services INC. | $22.32 | 2025 | |
| Blueprint Medicines Corporation | $21.44 | 2023 | Ayvakit |
| Tesaro, INC. | $20.08 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.79 | 2022 | |
| Sun Pharmaceutical Industries INC. | $19.34 | 2023 | Yonsa, Odomzo |
| Geron Corporation | $19.23 | 2025 | Rytelo |
| Jazz Pharmaceuticals INC. | $19.17 | 2023 | |
| Tersera Therapeutics LLC | $18.07 | 2024 | Zoladex |
| Aimmune Therapeutics, INC. | $17.13 | 2025 | Zenpep |
| Kite Pharma, INC. | $17.01 | 2022 | |
| Apellis Pharmaceuticals, INC. | $16.40 | 2023 | Empaveli |
| Pharmacosmos Therapeutics INC. | $15.43 | 2024 | Cosela |
| Clovis Oncology, INC. | $14.37 | 2019 | |
| Cti Biopharma Corp. | $14.24 | 2023 | Vonjo |
| Deciphera Pharmaceuticals INC. | $13.38 | 2022 | |
| G1 Therapeutics, INC. | $12.75 | 2022 | |
| Medtronic USA, INC. | $12.22 | 2019 | |
| Kyowa Kirin, INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohail Minhas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.